+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Optical Disorders Drugs Market Research Report by Prescription Type (Over-The-Counter Drugs and Prescription Ophthalmic Drugs), Therapeutics, End User, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 5305572
  • Report
  • April 2022
  • Region: Global
  • 206 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • Apollo Endosurgery
  • Cipla Pharmaceuticals
  • Eyegate Pharmaceuticals
  • Glaxosmithkline
  • Merck & Co.
  • Novartis AG
The Global Optical Disorders Drugs Market size was estimated at USD 2,462.17 million in 2021, USD 2,782.61 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 13.19% to reach USD 5,178.50 million by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Optical Disorders Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Prescription Type, the market was studied across Over-The-Counter Drugs and Prescription Ophthalmic Drugs.
  • Based on Therapeutics, the market was studied across Age-Related Macular Degeneration, Conjunctivitis, Diabetic Macular Edema, Diabetic Retinopathy, Dry Eye, Eye Cancer, Geographic Atrophy, Glaucoma, Keratitis, Lens Opacification and Intraocular Lens, and Retinal Vein Occlusion.
  • Based on End User, the market was studied across Diagnostic Centers Ophthalmic Drugs, Eye Clinics Ophthalmic Drugs, Hospitals, and Patient Ophthalmic Drugs.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.

This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Optical Disorders Drugs market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Optical Disorders Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Optical Disorders Drugs Market, including Apollo Endosurgery, Cipla Pharmaceuticals, Eyegate Pharmaceuticals, Glaxosmithkline, Merck & Co., Novartis AG, Pfizer, Inc., Roche Holding AG, Santen Pharmaceutical Co., Ltd, Senju Pharmaceutical Co., Ltd, and Sun Pharmaceuticals Industries, Ltd..

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Optical Disorders Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Optical Disorders Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Optical Disorders Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Optical Disorders Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Optical Disorders Drugs Market?
6. What is the market share of the leading vendors in the Global Optical Disorders Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Optical Disorders Drugs Market?
Frequently Asked Questions about the Global Optical Disorders Drugs Market

What is the estimated value of the Global Optical Disorders Drugs Market?

The Global Optical Disorders Drugs Market was estimated to be valued at $2462.2 Million in 2021.

What is the growth rate of the Global Optical Disorders Drugs Market?

The growth rate of the Global Optical Disorders Drugs Market is 13.1%, with an estimated value of $5178.5 Million by 2027.

What is the forecasted size of the Global Optical Disorders Drugs Market?

The Global Optical Disorders Drugs Market is estimated to be worth $5178.5 Million by 2027.

Who are the key companies in the Global Optical Disorders Drugs Market?

Key companies in the Global Optical Disorders Drugs Market include Apollo Endosurgery, Cipla Pharmaceuticals, Eyegate Pharmaceuticals, Glaxosmithkline, Merck & Co., Novartis AG, Pfizer, Inc., Roche Holding AG and Senju Pharmaceutical Co., Ltd.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Apollo Endosurgery
  • Cipla Pharmaceuticals
  • Eyegate Pharmaceuticals
  • Glaxosmithkline
  • Merck & Co.
  • Novartis AG

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. High stress, unhealthy lifestyles and increased digital exposure
5.1.1.2. Prevalence of eye related disorders in geriatric population
5.1.1.3. Rise in the use of contact lenses and related disorders
5.1.2. Restraints
5.1.2.1. High treatment cost and lack of health insurance in developing economies
5.1.3. Opportunities
5.1.3.1. Technological advancements in optic drugs
5.1.3.2. Rising prevalence of glaucoma and an increase in healthcare expenditure
5.1.4. Challenges
5.1.4.1. Lack of awareness and fear of treatment
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of 2022 Russia Ukraine Conflict
6. Optical Disorders Drugs Market, by Prescription Type
6.1. Introduction
6.2. Over-The-Counter Drugs
6.3. Prescription Ophthalmic Drugs
7. Optical Disorders Drugs Market, by Therapeutics
7.1. Introduction
7.2. Age-Related Macular Degeneration
7.3. Conjunctivitis
7.4. Diabetic Macular Edema
7.5. Diabetic Retinopathy
7.6. Dry Eye
7.7. Eye Cancer
7.8. Geographic Atrophy
7.9. Glaucoma
7.10. Keratitis
7.11. Lens Opacification and Intraocular Lens
7.12. Retinal Vein Occlusion
8. Optical Disorders Drugs Market, by End User
8.1. Introduction
8.2. Diagnostic Centers Ophthalmic Drugs
8.3. Eye Clinics Ophthalmic Drugs
8.4. Hospitals
8.5. Patient Ophthalmic Drugs
9. Americas Optical Disorders Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Optical Disorders Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
11. Europe, Middle East & Africa Optical Disorders Drugs Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Apollo Endosurgery
13.2. Cipla Pharmaceuticals
13.3. Eyegate Pharmaceuticals
13.4. Glaxosmithkline
13.5. Merck & Co.
13.6. Novartis AG
13.7. Pfizer, Inc.
13.8. Roche Holding AG
13.9. Santen Pharmaceutical Co., Ltd
13.10. Senju Pharmaceutical Co., Ltd
13.11. Sun Pharmaceuticals Industries, Ltd.
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL OPTICAL DISORDERS DRUGS MARKET: DYNAMICS
FIGURE 2. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2021 VS 2027 (%)
FIGURE 3. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2027
FIGURE 5. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2019-2027 (USD MILLION)
FIGURE 6. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 7. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION OPHTHALMIC DRUGS, 2019-2027 (USD MILLION)
FIGURE 8. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION OPHTHALMIC DRUGS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 9. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2021 VS 2027 (%)
FIGURE 10. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2021 VS 2027 (USD MILLION)
FIGURE 11. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2027
FIGURE 12. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2019-2027 (USD MILLION)
FIGURE 13. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 14. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY CONJUNCTIVITIS, 2019-2027 (USD MILLION)
FIGURE 15. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY CONJUNCTIVITIS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 16. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIABETIC MACULAR EDEMA, 2019-2027 (USD MILLION)
FIGURE 17. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 18. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIABETIC RETINOPATHY, 2019-2027 (USD MILLION)
FIGURE 19. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 20. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRY EYE, 2019-2027 (USD MILLION)
FIGURE 21. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRY EYE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 22. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY EYE CANCER, 2019-2027 (USD MILLION)
FIGURE 23. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY EYE CANCER, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 24. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHIC ATROPHY, 2019-2027 (USD MILLION)
FIGURE 25. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHIC ATROPHY, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 26. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY GLAUCOMA, 2019-2027 (USD MILLION)
FIGURE 27. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY GLAUCOMA, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 28. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY KERATITIS, 2019-2027 (USD MILLION)
FIGURE 29. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY KERATITIS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 30. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY LENS OPACIFICATION AND INTRAOCULAR LENS, 2019-2027 (USD MILLION)
FIGURE 31. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY LENS OPACIFICATION AND INTRAOCULAR LENS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 32. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2019-2027 (USD MILLION)
FIGURE 33. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 34. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2021 VS 2027 (%)
FIGURE 35. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2021 VS 2027 (USD MILLION)
FIGURE 36. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2027
FIGURE 37. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIAGNOSTIC CENTERS OPHTHALMIC DRUGS, 2019-2027 (USD MILLION)
FIGURE 38. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIAGNOSTIC CENTERS OPHTHALMIC DRUGS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 39. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY EYE CLINICS OPHTHALMIC DRUGS, 2019-2027 (USD MILLION)
FIGURE 40. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY EYE CLINICS OPHTHALMIC DRUGS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 41. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY HOSPITALS, 2019-2027 (USD MILLION)
FIGURE 42. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 43. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PATIENT OPHTHALMIC DRUGS, 2019-2027 (USD MILLION)
FIGURE 44. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PATIENT OPHTHALMIC DRUGS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 45. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 46. ARGENTINA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 47. BRAZIL OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 48. CANADA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 49. MEXICO OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 50. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 51. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 52. AUSTRALIA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 53. CHINA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 54. INDIA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 55. INDONESIA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 56. JAPAN OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 57. MALAYSIA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 58. PHILIPPINES OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 59. SINGAPORE OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 60. SOUTH KOREA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 61. TAIWAN OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 62. THAILAND OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 63. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 64. FRANCE OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 65. GERMANY OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 66. ITALY OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 67. NETHERLANDS OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 68. QATAR OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 69. RUSSIA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 70. SAUDI ARABIA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 71. SOUTH AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 72. SPAIN OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 73. UNITED ARAB EMIRATES OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 74. UNITED KINGDOM OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 75. GLOBAL OPTICAL DISORDERS DRUGS MARKET: FPNV POSITIONING MATRIX
FIGURE 76. GLOBAL OPTICAL DISORDERS DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 77. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL OPTICAL DISORDERS DRUGS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL OPTICAL DISORDERS DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2019-2027 (USD MILLION)
TABLE 4. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2019-2027 (USD MILLION)
TABLE 5. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 6. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY STATE, 2019-2027 (USD MILLION)
TABLE 7. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 8. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 9. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION OPHTHALMIC DRUGS, BY REGION, 2019-2027 (USD MILLION)
TABLE 10. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION OPHTHALMIC DRUGS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 11. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION OPHTHALMIC DRUGS, BY STATE, 2019-2027 (USD MILLION)
TABLE 12. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION OPHTHALMIC DRUGS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 13. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION OPHTHALMIC DRUGS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 14. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2019-2027 (USD MILLION)
TABLE 15. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2019-2027 (USD MILLION)
TABLE 16. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 17. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY STATE, 2019-2027 (USD MILLION)
TABLE 18. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 19. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 20. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY CONJUNCTIVITIS, BY REGION, 2019-2027 (USD MILLION)
TABLE 21. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY CONJUNCTIVITIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 22. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY CONJUNCTIVITIS, BY STATE, 2019-2027 (USD MILLION)
TABLE 23. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY CONJUNCTIVITIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 24. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY CONJUNCTIVITIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 25. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2019-2027 (USD MILLION)
TABLE 26. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 27. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY STATE, 2019-2027 (USD MILLION)
TABLE 28. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 29. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 30. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2019-2027 (USD MILLION)
TABLE 31. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIABETIC RETINOPATHY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 32. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIABETIC RETINOPATHY, BY STATE, 2019-2027 (USD MILLION)
TABLE 33. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIABETIC RETINOPATHY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 34. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIABETIC RETINOPATHY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 35. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRY EYE, BY REGION, 2019-2027 (USD MILLION)
TABLE 36. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRY EYE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 37. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRY EYE, BY STATE, 2019-2027 (USD MILLION)
TABLE 38. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRY EYE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 39. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRY EYE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 40. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY EYE CANCER, BY REGION, 2019-2027 (USD MILLION)
TABLE 41. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY EYE CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 42. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY EYE CANCER, BY STATE, 2019-2027 (USD MILLION)
TABLE 43. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY EYE CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 44. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY EYE CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 45. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHIC ATROPHY, BY REGION, 2019-2027 (USD MILLION)
TABLE 46. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHIC ATROPHY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 47. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHIC ATROPHY, BY STATE, 2019-2027 (USD MILLION)
TABLE 48. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHIC ATROPHY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 49. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHIC ATROPHY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 50. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY GLAUCOMA, BY REGION, 2019-2027 (USD MILLION)
TABLE 51. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY GLAUCOMA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 52. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY GLAUCOMA, BY STATE, 2019-2027 (USD MILLION)
TABLE 53. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY GLAUCOMA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 54. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY GLAUCOMA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 55. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY KERATITIS, BY REGION, 2019-2027 (USD MILLION)
TABLE 56. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY KERATITIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 57. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY KERATITIS, BY STATE, 2019-2027 (USD MILLION)
TABLE 58. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY KERATITIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 59. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY KERATITIS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 60. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY LENS OPACIFICATION AND INTRAOCULAR LENS, BY REGION, 2019-2027 (USD MILLION)
TABLE 61. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY LENS OPACIFICATION AND INTRAOCULAR LENS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 62. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY LENS OPACIFICATION AND INTRAOCULAR LENS, BY STATE, 2019-2027 (USD MILLION)
TABLE 63. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY LENS OPACIFICATION AND INTRAOCULAR LENS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 64. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY LENS OPACIFICATION AND INTRAOCULAR LENS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 65. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY REGION, 2019-2027 (USD MILLION)
TABLE 66. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 67. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY STATE, 2019-2027 (USD MILLION)
TABLE 68. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 69. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 70. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 71. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIAGNOSTIC CENTERS OPHTHALMIC DRUGS, BY REGION, 2019-2027 (USD MILLION)
TABLE 72. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIAGNOSTIC CENTERS OPHTHALMIC DRUGS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 73. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIAGNOSTIC CENTERS OPHTHALMIC DRUGS, BY STATE, 2019-2027 (USD MILLION)
TABLE 74. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIAGNOSTIC CENTERS OPHTHALMIC DRUGS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIAGNOSTIC CENTERS OPHTHALMIC DRUGS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 76. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY EYE CLINICS OPHTHALMIC DRUGS, BY REGION, 2019-2027 (USD MILLION)
TABLE 77. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY EYE CLINICS OPHTHALMIC DRUGS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 78. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY EYE CLINICS OPHTHALMIC DRUGS, BY STATE, 2019-2027 (USD MILLION)
TABLE 79. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY EYE CLINICS OPHTHALMIC DRUGS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY EYE CLINICS OPHTHALMIC DRUGS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 81. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2019-2027 (USD MILLION)
TABLE 82. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 83. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY HOSPITALS, BY STATE, 2019-2027 (USD MILLION)
TABLE 84. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 86. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PATIENT OPHTHALMIC DRUGS, BY REGION, 2019-2027 (USD MILLION)
TABLE 87. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY PATIENT OPHTHALMIC DRUGS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 88. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY PATIENT OPHTHALMIC DRUGS, BY STATE, 2019-2027 (USD MILLION)
TABLE 89. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY PATIENT OPHTHALMIC DRUGS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PATIENT OPHTHALMIC DRUGS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 91. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 92. ARGENTINA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 93. BRAZIL OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 94. CANADA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 95. MEXICO OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 96. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 97. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 98. AUSTRALIA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 99. CHINA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 100. INDIA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 101. INDONESIA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 102. JAPAN OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 103. MALAYSIA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 104. PHILIPPINES OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 105. SINGAPORE OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 106. SOUTH KOREA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 107. TAIWAN OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 108. THAILAND OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 110. FRANCE OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 111. GERMANY OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 112. ITALY OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 113. NETHERLANDS OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 114. QATAR OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 115. RUSSIA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 116. SAUDI ARABIA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 117. SOUTH AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 118. SPAIN OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 119. UNITED ARAB EMIRATES OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 120. UNITED KINGDOM OPTICAL DISORDERS DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 121. GLOBAL OPTICAL DISORDERS DRUGS MARKET: SCORES
TABLE 122. GLOBAL OPTICAL DISORDERS DRUGS MARKET: BUSINESS STRATEGY
TABLE 123. GLOBAL OPTICAL DISORDERS DRUGS MARKET: PRODUCT SATISFACTION
TABLE 124. GLOBAL OPTICAL DISORDERS DRUGS MARKET: RANKING
TABLE 125. GLOBAL OPTICAL DISORDERS DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 126. GLOBAL OPTICAL DISORDERS DRUGS MARKET: MERGER & ACQUISITION
TABLE 127. GLOBAL OPTICAL DISORDERS DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 128. GLOBAL OPTICAL DISORDERS DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 129. GLOBAL OPTICAL DISORDERS DRUGS MARKET: INVESTMENT & FUNDING
TABLE 130. GLOBAL OPTICAL DISORDERS DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 131. GLOBAL OPTICAL DISORDERS DRUGS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Apollo Endosurgery
  • Cipla Pharmaceuticals
  • Eyegate Pharmaceuticals
  • Glaxosmithkline
  • Merck & Co.
  • Novartis AG
  • Pfizer, Inc.
  • Roche Holding AG
  • Santen Pharmaceutical Co., Ltd
  • Senju Pharmaceutical Co., Ltd
  • Sun Pharmaceuticals Industries, Ltd.
Note: Product cover images may vary from those shown

Loading
LOADING...